BETA
Your AI-Trained Oncology Knowledge Connection!
Guidelines Validated for Anticoagulant Dose Reductions in Thrombocytopenia
A new study validates therapeutic guidelines that recommend anticoagulant dose reductions for thrombocytopenia in cancer patients.
RFA, SBRT Both Good Options for Unresectable Hepatocellular Carcinoma
Both radiofrequency ablation and stereotactic body radiotherapy are effective in the treatment of inoperable, non-metastatic hepatocellular carcinoma.
False-Positive Mammograms Linked to Later Breast Cancer Risk
Women who previously had a false-positive mammogram or biopsy are at higher risk for developing breast cancer for at least 10 years, according to a new study.
Drop in PSA Screening Rates After USPSTF Recommendations
Following the USPSTF recommendation in 2012 against routine PSA screening, rates of screening and the incidence of early-stage prostate cancer have both declined.
Latest Changes in Breast Cancer Screening Guidelines
In this interview we discuss the new American Cancer Society breast cancer screening guidelines and find out how they stack up with other recommendations for mammography screening.
November 2015 News Roundup
In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.
Frontline Nivolumab Approved for BRAF Wild-type Melanoma
Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.
Innovative GBM Trial Could Hasten Development of New Treatments
Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.
Higher PD-L1 Expression Associated With Worse Glioblastoma Survival
Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.
Complete Table of Contents 2017
The table of contents for the latest issue of the journal ONCOLOGY: Perspectives on the Treatment of Hematologic and Solid Malignancies.
Dendritic Cell Immunotherapy Promising in HLA-A2-Positive Glioblastoma
HLA-A2-positive glioblastoma patients experienced more frequent immune responses to the dendritic-cell immunotherapy IDT-107, responses that may be associated with improved survival.
Panitumumab Failed in KRAS Wild-Type Biliary Tract Cancer
Adding the EGFR-targeting drug panitumumab to chemotherapy had no effect on survival in a group of patients with wild-type KRAS status advanced biliary tract cancer.
Men’s Supplements Offer No Benefit in Prostate Cancer
For men with prostate cancer undergoing radiation therapy, consumption of men’s health supplements are unlikely to prevent adverse events, metastasis, or cancer-related death.
New ACS Guidelines Recommend Later, Less Frequent Breast Cancer Screening
New breast cancer screening guidelines from the American Cancer Society recommend pushing the start of screening back by 5 years and screening every other year rather than annually starting at age 55.
ASCO Updates Guidelines on Antiemetics
The American Society of Clinical Oncology (ASCO) updated their antiemetic guideline to include the use of a novel antiemetic combination for cancer patients.
Menopausal Status Could Guide Breast Cancer Screening Frequency
An analysis of different breast cancer screening schedules suggests that biennial mammograms may be acceptable for postmenopausal women, but that premenopausal women likely need more frequent screening.
Prostate Cancer
This management guide covers the treatment, diagnosis, and staging of prostate cancer.
Liver, Gallbladder, and Biliary Tract Cancers
This management guide covers the risk factors, symptoms, diagnosis, staging, and treatment of liver, gallbladder, and biliary tract cancers using radiation, surgery, and medical treatment.
Testicular Cancer
This testicular cancer management guide covers the diagnosis, staging, and treatment of germ-cell tumors and seminoma.
Esophageal Cancer
This comprehensive guide for oncologists covers the diagnosis, staging, treatment, and management of esophageal cancer.
Cervical Cancer
This management guide covers the screening, diagnosis, staging, and treatment of cervical cancers.
Uterine Corpus Tumors
Carcinoma of the epithelial lining (endometrium) of the uterine corpus is the most common female pelvic malignancy. Factors influencing its prominence are the declining incidence of cervical cancer, longer life expectancy, and earlier diagnosis.
AIDS-Related Malignancies
Malignancies have been detected in approximately 40% of all patients with acquired immunodeficiency syndrome (AIDS) sometime during the course of their illness.
Primary and Metastatic Brain Tumors
Intracranial neoplasms can arise from any of the structures or cell types present in the cranial vault, including the brain, meninges, pituitary gland, skull, and even residual embryonic tissue.
Carcinoma of an Unknown Primary Site
Carcinoma of an unknown primary site is a common clinical syndrome, accounting for approximately 3% of all oncologic diagnoses. Patients in this group are heterogeneous, having a wide variety of clinical presentations and pathologic findings.
Infectious Complications
Infections are among the most common, potentially serious complications of cancer and its treatment.
Fluid Complications
Malignant pleural effusion complicates the care of approximately 150,000 people in the United States each year.
Oncologic Emergencies and Paraneoplastic Syndromes
This management guide covers the oncologic emergencies such as superior vena cava syndrome, deep venous thrombosis, pulmonary embolism, and other paraneoplastic syndromes.
Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is the IV infusion of hematopoietic stem and progenitor cells designed to establish marrow and immune function in patients with a variety of acquired and inherited malignant and nonmalignant disorders.
Small-Cell Lung Cancer, Mesothelioma, and Thymoma
This management guide covers the symptoms, screening, diagnosis, and treatment of small-cell lung cancer (SCLC), mesothelioma, and thymoma from a surgical, medical, and radiation oncology approach.